CIK 0000730272 · Large accelerated filer
REPLIGEN CORP
Sign in to watch- Ticker
- RGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 042729386
- Phone
- 7814499560
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,953,260
- in 5 filings, $6.0M under 10b5-1 plans
Net −$5,953,260. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-05 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 | −1,333 | $178.75 | $238K | 45,788 |
| 2026-10-05 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 | −4,202 | $190.00 | $798K | 45,788 |
| 2026-09-24 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 | −8,404 | $190.00 | $1.6M | 48,369 |
| 2026-09-24 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 | −4,542 | $190.00 | $863K | 48,369 |
| 2026-09-21 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 | −5,426 | $180.00 | $977K | 48,369 |
| 2026-09-04 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 | −3,035 | $165.90 | $504K | 48,369 |
| 2026-08-20 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 | −5,426 | $180.00 | $977K | 54,246 |
| 2026-07-16 | Garland Jason K CFO | Sale 10b5-1 | −530 | $150.00 | $80K | 18,829 |
| 2026-06-25 | Garland Jason K CFO | Sale 10b5-1 | −733 | $145.00 | $106K | 19,359 |
| 2026-04-21 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 | −3,832 | $140.00 | $536K | 54,246 |
| 2025-12-17 | DAWES KAREN A Director | Sale | −275 | $161.00 | $44K | 91,821 |
| 2025-11-25 | Loeillot Olivier Chief Executive Officer | Sale 10b5-1 | −7,041 | $170.00 | $1.2M | 35,898 |
| 2025-11-18 | Bylund James Chief Operating Officer | Sale | −2,191 | $151.21 | $331K | 21,520 |
| 2025-11-13 | Hunt Anthony Director | Sale | −1,784 | $151.01 | $269K | 98,959 |
| 2025-11-13 | Hunt Anthony Director | Sale | −2,100 | $152.17 | $320K | 96,859 |
| 2025-11-13 | Hunt Anthony Director | Sale | −2,923 | $153.14 | $448K | 93,936 |
| 2025-11-13 | Hunt Anthony Director | Sale | −2,500 | $154.32 | $386K | 91,436 |
| 2025-11-13 | Hunt Anthony Director | Sale | −3,000 | $155.45 | $466K | 88,436 |
| 2025-11-13 | Hunt Anthony Director | Sale | −5,737 | $156.22 | $896K | 82,699 |
| 2025-11-13 | Hunt Anthony Director | Sale | −1,956 | $157.11 | $307K | 80,743 |
Page 1 of 3 · 56 trades